TP53 and metastatic neoplasm: In the advanced/metastatic disease setting, combination therapy is becoming the new standard-of-care frontline treatment in select high-risk groups, such as those with high tumor burden, baseline CNS or liver metastases, TP53 co-mutations or detectable ctDNA, though careful patient selection and counseling are essential given the added toxicity.